
    
      OBJECTIVES: I. Estimate the maximum tolerated dose of weekly intravenous doxorubicin (DOX)
      that can be given in combination with oral estramustine (EM) in patients with metastatic
      prostate cancer refractory to treatment with hormonal agents. II. Assess the frequency of
      expression of the multidrug resistance phenotype in biopsy specimens from these patients.
      III. Assess the response to DOX/EM in these patients.

      OUTLINE: 2-Drug Combination Chemotherapy. Doxorubicin, DOX, NSC-123127; Estramustine, EM,
      NSC-89199.

      PROJECTED ACCRUAL: Three to 18 patients will be entered.
    
  